---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-075944"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:59:19.765847+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics reports Q2 2025: VCN-01 Phase 2b success, cash $12.1M, runway into Q1 2026

## Summary
- Positive topline from VIRAGE Phase 2b: VCN-01 plus chemo improved OS, PFS, DOR vs chemo alone in metastatic pancreatic cancer.
- Cash and cash equivalents $12.1M as of June 30, 2025; early Aug cash $9.5M, expected runway into Q1 2026.
- G&A expenses $11.2M (up 662% YoY) due to $9.2M contingent consideration adjustment from VIRAGE success; R&D $2.0M (down 34%).
- Expanded VIRAGE data to be presented at ESMO 2025 Congress in October.
- Phase 1 retinoblastoma data of VCN-01 presented at ASCO 2025.

## SEC filing metadata
- accession: 0001104659-25-075944
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925075944/0001104659-25-075944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925075944/tm2522967d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-075944
- JSON: https://secwatch.observer/filing/0001104659-25-075944.json
- Plain text: https://secwatch.observer/filing/0001104659-25-075944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.